The NCBP3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model targeting the NCBP3 gene in the human Raji B lymphocyte line. This polyclonal knockout cell population enables loss-of-function studies of the nuclear cap-binding complex (CBC) subunit without clonal selection, providing a heterogeneous pool of edited cells suitable for pooled functional screens and population-based analyses. The product serves as a versatile tool for investigating post-transcriptional gene regulation in a malignant B cell background.
Raji cells are an Epstein-Barr virus (EBV)-positive human Burkitt lymphoma line derived from a patient with African Burkitt lymphoma. They exhibit characteristic B cell features, including surface immunoglobulin expression and B cell markers, and are widely used as a model for B cell malignancies and immune signaling research. Their EBV-positive status makes them particularly relevant for studying viral manipulation of host RNA metabolism, rendering the NCBP3 knockout in this context valuable for dissecting both cellular and viral RNA processing.
NCBP3 encodes a component of the nuclear cap-binding complex, which binds the 7-methylguanosine cap of RNA polymerase II transcripts. Together with NCBP1 and NCBP2, NCBP3 participates in pre-mRNA splicing, 3??-end formation, and mRNA export. It functions downstream of cap addition, interacting with the adaptor protein ALYREF and the TREX complex to facilitate nucleocytoplasmic transport through the nuclear pore complex. NCBP3 is also implicated in cap-dependent translation initiation. Disruption of NCBP3 thus compromises CBC integrity, leading to broad defects in mRNA processing and export.
In the Raji lymphoma model, NCBP3 knockout allows dissection of CBC-dependent RNA metabolism in a B cell cancer context. Aberrations in mRNA export and translation are increasingly recognized as contributors to lymphomagenesis. Moreover, EBV exploits host CBC components to enhance viral RNA biogenesis and evade immune detection. By ablating NCBP3, researchers can examine how loss of CBC function alters B cell proliferation, apoptosis, and viral transcript handling, providing insights into potential vulnerabilities in lymphoma and EBV-associated diseases.
Typical applications include mechanistic studies of mRNA export using polyA RNA FISH or polysome profiling, transcriptome-wide analysis via RNA-seq, and cap-binding assays to evaluate CBC activity. Functional assays such as proliferation and apoptosis measurements can assess the impact on lymphoma cell fitness, while RT-qPCR or RNA-seq can quantify EBV transcript alterations. This product is suitable for functional genomics screens in B cells and investigation of nuclear transport pathways. For further inquiries, please contact Ascent Research.
